British journal of haematology 2020 May 01
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib.
Related Questions
As the cost of NGS decreases over time, is there still a need for more focused/targeted panels such as JAK2, CALR, and MPL? Are other genes important ...